[REVISION HISTORY]

U.S. legal challenges to mifepristone access

Updated 1 time since CLSTR started tracking revisions of this situation.

What changed

2026-09-09 10:43 UTC → 2026-09-10 04:11 UTC · added ~~removed~~

Legal challenges regarding the nationwide availability of the abortion medication mifepristone have progressed through the U.S. federal court system. In late August, U.S. Chief District Judge Reed O’Connor paused a federal lawsuit filed by the attorneys general of Florida and Texas that sought to revoke the Food and Drug Administration’s (FDA) approval of the drug. The stay was granted to allow the FDA to complete a safety review, delaying a decision until at least December 1. Following this, the 5th U.S. Circuit Court of Appeals scheduled arguments regarding potential restrictions on the medication. This legal movement aims to limit access by preventing clinicians in states where abortion is legal from mailing pills to patients in states with bans or tighter restrictions. The FDA is also reportedly reassessing current prescribing requirements and may recommend regulatory changes. On September 9, the 5th U.S. Circuit Court of Appeals in New Orleans heard arguments concerning the regulation of the drug. The challenge, brought by Louisiana Attorney General Liz Murrill, focuses on whether current federal regulations allow a “workaround” to state laws by enabling telehealth and mail-order access. Advocates for access argue that restricting these methods would disproportionately impact patients, while proponents of the lawsuit question the FDA’s authority and the adequacy of its safety studies regarding loosened prescribing requirements. Although the Supreme Court previously ordered that current telehealth access be maintained during litigation, the outcome of these appeals is expected to return to the high court for a final determination.

Versions

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.